SAN FRANCISCO, Feb. 6, 2013 /PRNewswire/ -- Medizone International (MZEI:OB MZEI:QB), developers of AsepticSure – a unique room disinfection system capable of obtaining sustained > 6 log (>99.9999%) broad spectrum bactericidal kill rates in a health care setting – announced today that Singapore has joined Canada in Granting a patent for its international award-winning technology. (Singapore Patent P-No.: 176977 Healthcare Facility Disinfecting Process and System With Oxygen/Ozone Mixture)
Medizone's CEO Edwin Marshall commented, "This is our first patent grant for the Asian market. As reported by Asiaone, your Health, Singapore saw an estimated 850,000 foreign patients in 2012 with estimated revenues from medical tourism of US$3.5 billion. The medical tourism growth rate is projected to be 15 to 20% annually through 2015."
Marshall went on, "Preliminary market research in Asia has confirmed that many leading hospitals in the medical tourism market will welcome AsepticSure as a key component to offering the safest hospitals possible, and to ensuring their future growth in this lucrative market."
Plans for a staged launch of AsepticSure into Asia are in the early development phase.
Medizone has also made national filings of its health care application in South Korea, Japan, China, India, the United States, Mexico, Brazil and the European Union (including Great Britain.)
These filings were made following release of a favorable Report of the International Preliminary Examination Authority in the International stage of the patent application process.
For press information on Medizone International, please contact:
Bruce Smeaton , Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure® Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com
SOURCE Medizone International, Inc.